Yvonne Mårtensson will leave her position as President/CEO of CellaVision at year end 2014.

This information was released for public disclosure on May 6, 2014 at 8.20 am CET.

Yvonne Mårtensson remains CEO until a successor is appointed or until 31 December 2014 at the latest. Yvonne Mårtensson has been CEO since 1998.

"I have had the privilege of being part of this exciting journey that started sixteen years ago. Together with fantastic colleagues I was able to take CellaVision from an invention and a few developers to an established medical technology company with 70 employees in Europe, North America and Asia. I am proud of having built a stable company with strong shared values, as a platform for continued development and growth," says Yvonne Mårtensson.

Since Yvonne Mårtensson joined CellaVision as CEO in 1998 CellaVision has progressed from being an exciting innovation company to a global market leader in digital solutions for medical microscopy in hematology. In 2013 the company's sales were SEK 180 million, with an operating margin of almost 15 per cent. CellaVision's products are used in some 2,000 laboratories in more than 50 countries.

The company has been listed on Nasdaq OMX Stockholm since 2010.

"In her sixteen years as President/CEO of CellaVision Yvonne Mårtensson has done an unprecedented job of building the company into the global medical technology innovation company it is today. We hold a very strong position in the business segment where we operate, based on focusing on customer satisfaction and developing solutions that give patient benefit and efficiencies in healthcare. With her leadership and operative skill Yvonne has achieved deeply impressive work," says Lars Gatenbeck, Chairman of the Board.

The work of recruiting a new President/CEO will be started and Yvonne Mårtensson will remain in the position as CEO until a successor is in place. She will stay in the company until the year end in order to maintain the continuity and secure a smooth transition.


Lars Gatenbeck

Chairman of the Board


For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46708337782 | Email: yvonne.martensson@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2013 sales were SEK 180 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.

Press release as PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cellavision AB via Globenewswire
HUG#1782894